Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Aug 06 2014 Cyclacel Pharmaceuticals to Release 2014 Second Quarter Financial Results Jun 17 2014 Cyclacel Pharmaceuticals to Present at 9th Annual JMP Securities Healthcare Conference May 31 2014 Cyclacel Pharmaceuticals Provides Update on Its Clinical Development Plan of Sapacitabine for Myelodysplastic Syndromes (MDS) May 28 2014 Cyclacel Pharmaceuticals to Webcast Institutional Investor and Analyst Presentation on Clinical Development Plan of Sapacitabine for MDS May 13 2014 Cyclacel Pharmaceuticals Reports First Quarter 2014 Financial Results May 06 2014 Cyclacel Pharmaceuticals to Release 2014 First Quarter Financial Results May 05 2014 New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations and Combination Treatments Apr 10 2014 Independent Investigators Present Non-Clinical Data Providing Rationale for Sapacitabine Combination Treatment With Bcr-Abl Inhibitors in CML Apr 09 2014 Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering Apr 04 2014 Cyclacel Pharmaceuticals Announces $10 Million Underwritten Offering Apr 03 2014 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock Mar 25 2014 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results Mar 13 2014 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results Feb 03 2014 Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference Jan 13 2014 Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014 Jan 06 2014 Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference Dec 09 2013 Cyclacel Reports New Phase 2 Data of Sapacitabine for MDS at ASH Dec 09 2013 2013 ASH 682-06 MDS Poster Nov 25 2013 Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML Nov 12 2013 Cyclacel Reports Third Quarter 2013 Financial Results Nov 07 2013 Researchers to Present New Phase 2 Data on Sapacitabine as a Treatment for Patients With MDS at ASH Annual Meeting Nov 06 2013 Cyclacel Pharmaceuticals to Release Third Quarter 2013 Financial Results Nov 05 2013 New US Patents Issued Covering Sapacitabine Use With Hypomethylating Agents and Sapacitabine Dosing Regimens Oct 31 2013 Cyclacel Pharmaceuticals to Present at the 2013 Therapeutic Area Partnerships Conference Sep 19 2013 Cyclacel's Sapacitabine Reported to Have Anti-Tumor Activity Against Ovarian Cancer Pagination First page « first Previous page ‹ previous … Page 6 Page 7 Page 8 Page 9 Current page 10 Page 11 Page 12 Page 13 Page 14 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Aug 06 2014 Cyclacel Pharmaceuticals to Release 2014 Second Quarter Financial Results Jun 17 2014 Cyclacel Pharmaceuticals to Present at 9th Annual JMP Securities Healthcare Conference May 31 2014 Cyclacel Pharmaceuticals Provides Update on Its Clinical Development Plan of Sapacitabine for Myelodysplastic Syndromes (MDS) May 28 2014 Cyclacel Pharmaceuticals to Webcast Institutional Investor and Analyst Presentation on Clinical Development Plan of Sapacitabine for MDS May 13 2014 Cyclacel Pharmaceuticals Reports First Quarter 2014 Financial Results May 06 2014 Cyclacel Pharmaceuticals to Release 2014 First Quarter Financial Results May 05 2014 New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations and Combination Treatments Apr 10 2014 Independent Investigators Present Non-Clinical Data Providing Rationale for Sapacitabine Combination Treatment With Bcr-Abl Inhibitors in CML Apr 09 2014 Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering Apr 04 2014 Cyclacel Pharmaceuticals Announces $10 Million Underwritten Offering Apr 03 2014 Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock Mar 25 2014 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results Mar 13 2014 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results Feb 03 2014 Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference Jan 13 2014 Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014 Jan 06 2014 Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference Dec 09 2013 Cyclacel Reports New Phase 2 Data of Sapacitabine for MDS at ASH Dec 09 2013 2013 ASH 682-06 MDS Poster Nov 25 2013 Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML Nov 12 2013 Cyclacel Reports Third Quarter 2013 Financial Results Nov 07 2013 Researchers to Present New Phase 2 Data on Sapacitabine as a Treatment for Patients With MDS at ASH Annual Meeting Nov 06 2013 Cyclacel Pharmaceuticals to Release Third Quarter 2013 Financial Results Nov 05 2013 New US Patents Issued Covering Sapacitabine Use With Hypomethylating Agents and Sapacitabine Dosing Regimens Oct 31 2013 Cyclacel Pharmaceuticals to Present at the 2013 Therapeutic Area Partnerships Conference Sep 19 2013 Cyclacel's Sapacitabine Reported to Have Anti-Tumor Activity Against Ovarian Cancer Pagination First page « first Previous page ‹ previous … Page 6 Page 7 Page 8 Page 9 Current page 10 Page 11 Page 12 Page 13 Page 14 … Next page next › Last page last »
May 31 2014 Cyclacel Pharmaceuticals Provides Update on Its Clinical Development Plan of Sapacitabine for Myelodysplastic Syndromes (MDS)
May 28 2014 Cyclacel Pharmaceuticals to Webcast Institutional Investor and Analyst Presentation on Clinical Development Plan of Sapacitabine for MDS
May 05 2014 New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations and Combination Treatments
Apr 10 2014 Independent Investigators Present Non-Clinical Data Providing Rationale for Sapacitabine Combination Treatment With Bcr-Abl Inhibitors in CML
Nov 25 2013 Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML
Nov 07 2013 Researchers to Present New Phase 2 Data on Sapacitabine as a Treatment for Patients With MDS at ASH Annual Meeting
Nov 05 2013 New US Patents Issued Covering Sapacitabine Use With Hypomethylating Agents and Sapacitabine Dosing Regimens
